Last reviewed · How we verify
oxybuprocaine
oxybuprocaine is a drug. It is currently in unknown development for Topical local anesthetic to eye.
Oxybuprocaine is a small molecule local anesthetic used in ophthalmology and otolaryngology. It is available under brand names such as Novesine or Novesin, and has been studied for use in anesthesia during procedures such as adenotonsillectomy and airway management.
At a glance
| Generic name | oxybuprocaine |
|---|---|
| Target | Sodium channel protein type 10 subunit alpha, Sodium channel alpha subunits; brain (Types I, II, III) |
| Therapeutic area | Ophthalmology |
| Phase | unknown |
Approved indications
- Topical local anesthetic to eye
Common side effects
Key clinical trials
- Swiss PACK-CXL (Photoactivated Chromophore for Infectious Keratitis Cross-linking) Multicenter Trial for the Treatment of Infectious Keratitis (Phase 3)
- A Double Blinded Randomized Controlled Study of Topical Anaesthetics Oxybuprocaine Versus Bupivacaine 0.5% in Intravitreal Injections (EARLY/Phase 1)
- Hemodynamic Response Of Premature Brain To Pain During Retinopathy Of Prematurity Screening: A Randomized Controlled Trial (Phase 4)
- Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema and Retinal Vein Occlusion Patients (EARLY/Phase 1)
- Effect of Benoxinate Hydrochloride Eye Drops on The Premature Infant Pain Profile Score During Retinopathy of Prematurity Screening (Phase 3)
- Pain Control and Subconjunctival Hemorrhage Size After Intravitreal Injection Using Cooled Anesthetic Eye Drops and Antiseptics: A Double-Blind Randomized Controlled Trial (NA)
- An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of the Drug Grammidin With Anesthetic, a Metered Dose Topical Spray Following Single Administration in Healthy Vol (Phase 1)
- Anxiety-related Fixation Instability During Laser in Situ Keratomileusis (LASIK) (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxybuprocaine CI brief — competitive landscape report
- oxybuprocaine updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about oxybuprocaine
What is oxybuprocaine?
What is oxybuprocaine used for?
What development phase is oxybuprocaine in?
What does oxybuprocaine target?
Related
- Target: All drugs targeting Sodium channel protein type 10 subunit alpha, Sodium channel alpha subunits; brain (Types I, II, III)
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Topical local anesthetic to eye
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing